- Home
- NVO
NVO
Novo Nordisk A/S
as 06-28-2024 4:00pm EST
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
| Founded: | 1923 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 627.1B | IPO Year: | N/A |
| Target Price: | $140.50 | AVG Volume (30 days): | 3.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | 0.68% | Dividend Payout Frequency: | Semi-Annual |
| EPS: | 2.86 | EPS Growth: | 47.44 |
| 52 Week Low/High: | $75.56 - $148.15 | Next Earning Date: | 08-08-2024 |
| Revenue: | $35,346,309,696 | Revenue Growth: | 29.72% |
| Revenue Growth (this year): | 26.45% | Revenue Growth (next year): | 20.82% |
Latest Novo Nordisk A/S News
NVO Breaking Stock News: Dive into NVO Ticker-Specific Updates for Smart Investing
Motley Fool
a day ago
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Zacks
2 days ago
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
Argus Research
2 days ago
Technical Assessment: Bullish in the Intermediate-Term
Zacks
3 days ago
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
Yahoo Finance
3 days ago
Walgreens cuts EPS guidance, plans to close more stores
Investor's Business Daily
3 days ago
Eli Lilly Has Sprinted 55% Higher This Year — Is It A Buy On The Weight-Loss Opportunity?
Benzinga
3 days ago
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
Pharmaceutical Technology
3 days ago
2seventy bio completes $40m haemophilia A program deal with Novo Nordisk
Share on Social Networks:
Disclaimer
The information presented on this page, "NVO Novo Nordisk A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.